We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

84 hedge funds and large institutions have $1.31B invested in Theravance Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 25

0% more funds holding

Funds holding: 84 → 84 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

1.2% less ownership

Funds ownership: 87.94% → 86.74% (-1.2%)

19% less capital invested

Capital invested by funds: $1.62B → $1.31B (-$312M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

100% less call options, than puts

Call options by funds: $2K | Put options by funds: $944K

Holders
84
Holders Change
–
Holders Change %
0%
% of All Funds
1.91%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
11
Increased
30
Reduced
25
Closed
11
Calls
$2K
Puts
$944K
Net Calls
-$942K
Net Calls Change
+$851K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.12M
2
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D
New Jersey
+$1.92M
3
Deutsche Bank
Deutsche Bank
Germany
+$1.45M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.44M
5
WIM
Woodford Investment Management
United Kingdom
+$1.21M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.16M
2
First Manhattan
First Manhattan
New York
-$4.71M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$2.72M
4
BlackRock
BlackRock
New York
-$1.81M
5
Goldman Sachs
Goldman Sachs
New York
-$1.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
WIM
1
Woodford Investment Management
United Kingdom
$300M +$1.21M +41,000 +0.4%
BG
2
Baupost Group
Massachusetts
$260M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$222M +$1.44M +48,586 +0.6%
BlackRock
4
BlackRock
New York
$104M -$1.81M -61,272 -2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$94.8M +$3.12M +105,277 +3%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$64.6M +$451K +15,244 +0.7%
First Manhattan
7
First Manhattan
New York
$40.6M -$4.71M -159,000 -10%
CAM
8
Cormorant Asset Management
Massachusetts
$25.1M -$1.48M -50,000 -5%
State Street
9
State Street
Massachusetts
$24.6M -$910K -30,740 -3%
Norges Bank
10
Norges Bank
Norway
$21.6M -$844K -28,530 -4%
RSCM
11
Rock Springs Capital Management
Maryland
$18.2M +$243K +8,200 +1%
Northern Trust
12
Northern Trust
Illinois
$14.3M -$422K -14,253 -3%
FAM
13
Foundation Asset Management
New York
$12.1M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$10.4M +$391K +13,217 +4%
C
15
Chescapmanager
Maryland
$8.17M +$340K +11,480 +4%
State of New Jersey Common Pension Fund D
16
State of New Jersey Common Pension Fund D
New Jersey
$6.29M +$1.92M +65,000 +41%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$5.88M +$10.4K +350 +0.2%
Charles Schwab
18
Charles Schwab
California
$5.57M +$240K +8,119 +4%
Goldman Sachs
19
Goldman Sachs
New York
$5.51M -$1.75M -59,190 -23%
BNP Paribas Asset Management
20
BNP Paribas Asset Management
France
$4.91M +$40.5K +1,368 +0.8%
SAM
21
Senzar Asset Management
New York
$4.79M -$305K -10,300 -6%
Wells Fargo
22
Wells Fargo
California
$3.78M +$543K +18,335 +16%
TCIM
23
TIAA CREF Investment Management
New York
$3.51M -$219K -7,417 -6%
OWIM
24
Old West Investment Management
California
$3.17M -$2.37K -80 -0.1%
Deutsche Bank
25
Deutsche Bank
Germany
$3.03M +$1.45M +49,137 +82%
1
2 3 4

TBPH Hedge Fund Activity: Q4 2017 in Review

84 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2017, worth a combined $1.31B — down 19% from $1.62B a quarter earlier.

Fund positioning in TBPH was balanced in Q4 2017: 11 funds opened new positions, 11 closed out, 30 added to existing stakes and 25 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.12M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.16M sold.

  • 84 institutional investors held Theravance Biopharma (TBPH) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $1.31B of Theravance Biopharma stock for Q4 2017, down 19% quarter-over-quarter.
  • 11 funds opened new Theravance Biopharma positions in Q4 2017 and 11 closed out, a net change of 0 holders.
  • The largest Theravance Biopharma buyer in Q4 2017 was Vanguard Group, an estimated $3.12M added.
  • The largest Theravance Biopharma seller in Q4 2017 was Opaleye Management, an estimated $6.16M sold.

Based on aggregated 13F filings for Q4 2017.